(PDF) Ce4 - Cost-Effectiveness Analysis of First-Line

Ce4 - Cost-Effectiveness Analysis of First-Line Osimertinib in Patients With Egfr Mutation-Positive Non-Small Cell Lung Cancer

Value in Health - United Kingdom

doi 10.1016/j.jval.2018.09.016

Full Text

Abstract

Available in full text

Categories

Occupational Health

Date

October 1, 2018

Authors

C.A. Uyl-de Groot

Publisher

Elsevier BV

Related search

Cost‐Effectiveness of Osimertinib in Treating Newly Diagnosed, Advanced EGFR‐Mutation‐Positive Non‐Small Cell Lung Cancer

Cancer Research

English

Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients With EGFR-T790M Mutation

Cancer Research

English

P043 Cost-Effectiveness Analysis of Different Sequences of Osimertinib Administration for EGFR-Mutated Non-Small-Cell Lung Cancer

Journal of Thoracic Oncology

Respiratory Medicine

English

Clinical Analysis of EGFR‐ Positive Non‐small Cell Lung Cancer Patients Treated With First‐line Afatinib: A Nagano Lung Cancer Research Group

Thoracic Cancer

Respiratory Medicine

English

P2.13-42 Osimertinib Treatment for Patients With EGFR Exon 20 Insertion Positive Non-Small-Cell Lung Cancer

Journal of Thoracic Oncology

Respiratory Medicine

English

P1.01-77 Osimertinib in the First-Line Treatment of Non-Small Cell Lung Cancer Harboring Activating EGFR Mutation From Circulating Tumor DNA

Journal of Thoracic Oncology

Respiratory Medicine

English

Cost-Effectiveness of First-Line Erlotinib in Patients With Advanced Non-Small-Cell Lung Cancer Unsuitable for Chemotherapy

English

P2.01-29 Economic Analysis of Osimertinib in Previously Untreated EGFR-Positive Advanced Non-Small Cell Lung Cancer

Journal of Thoracic Oncology

Respiratory Medicine

English

Pcn44 - First-Line Treatment Efficacy in Egfr-Positive Non-Small Cell Lung Cancer: A Network Meta-Analysis

Value in Health

Occupational Health

English